Key facts
- This page summarizes Ansbert Gadicke's Form 4 filing for Repare Therapeutics Inc. (RPTX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Jun 2021, 16:07.
Ansbert Gadicke - 24 Jun 2021 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- RPTX
- Reported as of
- 24 Jun 2021
- Net transaction value
- -$961,457
- SEC form
- 4
- Accepted by SEC
- 28 Jun 2021, 16:07:42 UTC
- Prior SEC filing
- 23 Jun 2021
- Next SEC filing
- 30 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ansbert Gadicke
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ansbert Gadicke filed Form 4 for Repare Therapeutics Inc. (RPTX) on 28 Jun 2021.
Change
- Previous filing in this sequence was filed on 23 Jun 2021.
- Current net transaction value: -$961,457.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RPTX
transaction
Common Shares
Sale
- Transaction value
- $205,237
- Shares
- -6,121
- Change %
- -0.15%
- Price
- $33.53
- Shares after
- 3,986,331
- Date
- 24 Jun 2021
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3, F4
RPTX
transaction
Common Shares
Sale
- Transaction value
- $756,220
- Shares
- -22,567
- Change %
- -0.57%
- Price
- $33.51
- Shares after
- 3,963,764
- Date
- 25 Jun 2021
- Ownership
- See Footnote
- Footnotes
- F1, F5, F6, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.
Footnote F2
The shares were sold as follows: 2,607 by MPM BioVentures 2014, L.P. ("BV 2014"), 90 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 3,424 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.11 to $33.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The shares are held as follows: 2,080,922 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,625 by AM BV2014 and 1,697,941 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Footnote F5
The shares were sold as follows: 9,612 by BV 2014, 331 by AM BV2014 and 12,624 by UBS Oncology.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.10 to $33.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F7
The shares are held as follows: 2,071,310 by BV 2014, 135,843 by BV 2014(B), 71,294 by AM BV2014 and 1,685,317 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.